News | July 15, 2022
Evonik now offers enteric protected ready to fill capsules EUDRACAP in IPEC-GMP quality
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
Syngene's collaboration with Zoetis started in 2011
This acquisition is in line with Cipla's strategic imperative to augment the company's wellness portfolio for bringing about a shift from an illness to a wellness mindset.
The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds
The combined company will be able to better serve both our global and regional customers with local production
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
.jpg)
Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
This GMP and Pre-Approval Inspection is part of the routine business operations and the company shall submit to US FDA within the stipulated timeline
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Subscribe To Our Newsletter & Stay Updated
